6 December 2021 - Pharmaceutical Research and Manufacturers of America President and CEO Stephen J. Ubl released the following statement after President Joe Biden delivered remarks on drug pricing reform provisions in the Build Back Better Act:

"A damaging bill jammed through a partisan process will not provide patients struggling to afford their medicines meaningful relief. The bill inserts the heavy hand of government into America’s medicine cabinet, and we know when government bureaucrats set the price of medicine, patients ultimately have less access to treatments and cures. The bill also stifles the development of new uses for and improvements to medicines after they are first approved, threatens the introduction of generic and biosimilar medicines, and unwinds successful incentives that spur the development of treatments for rare diseases."

Read Pharmaceutical Research and Manufacturers of America press release